# Ponsegromab

Source: https://onco.cc/drugs/ponsegromab/  
OnCo record `ponsegromab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.

## Summary

Ponsegromab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by Pfizer, in pancreatic ductal adenocarcinoma. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Ponsegromab: https://clinicaltrials.gov/search?intr=Ponsegromab

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- trials: [A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue](https://onco.cc/trials/nct06989437/)

---
JSON: https://onco.cc/api/v1/entities/ponsegromab.json